Electrical Components and Equipment

SANXING

SANXING released FY2026 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 3.237 B, actual EPS CNY 0.12

SANXING released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 3.281 B (forecast CNY 4.074 B), actual EPS CNY -0.179 (forecast CNY 0.0783)

SANXING released FY2025 earnings on April 24 After-Market (BJT), actual revenue CNY 14.36 B (forecast CNY 15.38 B), actual EPS CNY 0.9 (forecast CNY 1.4533)

SANXING to Release FY2025 Earnings on April 25 After-Market (BJT), Forecast Revenue CNY 15.38 B, EPS CNY 1.4533

SANXING to Release FY2026 Q1 Earnings Report on April 25 Pre-Market BJT

SANXING released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 3.108 B (forecast CNY 3.994 B), actual EPS CNY 0.2103 (forecast CNY 0.527)

SANXING released FY2025 9 Months earnings on October 29 Pre-Market (BJT), actual revenue CNY 11.08 B, actual EPS CNY 1.0785

SANXING to Release FY2025 Q3 Earnings on October 30 Pre-Market (BJT), Forecast Revenue CNY 3.994 B, EPS CNY 0.527

SANXING released FY2025 Q2 earnings on August 21 After-Market BJT, actual revenue CNY 4.341 B (forecast CNY 4.717 B), actual EPS CNY 0.5181 (forecast CNY 0.6466)

SANXING released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 7.972 B, actual EPS CNY 0.87

SANXING to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Samsung Medical wins CPFL transformer procurement framework contract in Brazil

Ningbo Samsung Medical Electrical Co., Ltd. Submits New Trademark Application and Increases R&D Investment

Aoxle Smart Technology Wins 143 Million Yuan Project from State Grid

Everbright Seafront Securities Rates Samsung Medical as a Buy

Samsung Medical and Subsidiary win bids for State Grid procurement projects

Samsung Medical Overseas Distribution Business Progresses Smoothly, Meeting Expectations

Samsung Medical Reports Revenue and Net Profit Growth in Q1 2025

SANXING released FY2024 annual earnings on April 24 After-Market (BJT), actual revenue CNY 14.6 B (forecast CNY 14.63 B), actual EPS CNY 1.6 (forecast CNY 1.646)

SANXING released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 4.167 B, actual EPS CNY 0.3111

601567

Sanxing Medical Electric's shares surged by 10% to CNY29.41 after securing a EUR117 million (USD136.5 million) transformer order from Dutch client Enexis Netbeheer. This marks a significant breakthrough for the company in the Western European market. The order involves supplying oil-immersed transformers, crucial for power grid distribution and infrastructure. Sanxing Medical's revenue from power equipment constituted 80% of its total in the first half of last year, with recent successes in Europe and Latin America.

Yicai

Sanxing Medical Jumps by Limit After Bagging USD136.5 Million Transformer Order From Dutch Client

002922

688676

600406

The super cycle of power grid equipment is approaching, with the State Grid Corporation planning to invest 4 trillion yuan during the "14th Five-Year Plan" period to promote the high-quality development of the power system. In the next 10 years, Europe needs to invest 3 trillion euros, while the United States is expected to invest 700 billion dollars to upgrade the grid. The global power grid equipment faces structural shortages, and Chinese power equipment companies are expanding into the global market with high delivery efficiency and cost advantages. Goldman Sachs pointed out that investment in the power grid will continue to grow, especially in distribution infrastructure

- China's investment plan during the 14th Five-Year period is expected to reach 4 trillion yuan, significantly boosting the electric grid's development amid increasing demand for non-fossil energy sources.  
- Globally, there is a shift towards modernizing aging grids in the U.S. and Europe, driven by the need for enhanced efficiency and the rise of AI data centers, creating opportunities for Chinese power equipment firms.  
- As these companies expand internationally, they aim to capitalize on their cost advantages and delivery efficiencies, positioning themselves as key players in the global energy transition.

Wallstreetcn

EAGLERISE (CHINA)

Eaton

Jinpan Smart Technology

NARI-TECH

Super Cycle of Power Grid Equipment: "14th Five-Year Plan" Investment of 4 Trillion, Orders from Europe and America Ready to Surge

688206

As global markets fluctuate, investors are focusing on Asian companies with strong growth potential and high insider ownership. Quzhou Xin'an Development, with a 17.2% insider ownership and projected revenue growth of 47.6%, stands out despite financial health concerns. Other notable companies include Ningbo Sanxing Medical Electric, expected to grow earnings by 28.1%, and Primarius Technologies, with a 16.1% insider ownership and a revenue growth forecast of 19.7%. These companies reflect a trend towards investing in firms with significant insider confidence amid market volatility.

Simplywall

PRIMARIUS

Asian Growth Companies With High Insider Ownership Led By Quzhou Xin'an Development

301589

688278

Asian stocks are estimated to be up to 26% below intrinsic value, presenting growth opportunities for investors. Key undervalued stocks include Xi'an NovaStar Tech, Xiamen Amoytop Biotech, and Ningbo Sanxing Medical Electric, among others. Despite volatility, these stocks show potential for significant earnings growth. The article highlights the importance of identifying undervalued stocks in a complex market environment, offering insights into their financial health and growth forecasts.

Novastar

AMOYTOP

Asian Market Stocks Estimated Up To 26% Below Intrinsic Value

SANXING Medical and its subsidiaries have been recommended as candidates for winning bids in multiple procurement projects of the State Grid, with a total expected bid amount of approximately 193 million yuan

Zhitong

SANXING Medical and its subsidiaries are expected to win a bid for a National Grid project worth approximately 193 million yuan

Ningbo SANXING Medical Electric Co., Ltd. announced that it will repurchase and cancel 41,800 restricted shares due to the departure of 5 incentive targets who do not meet the incentive conditions. The cancellation is expected to be completed on September 12, 2025, after which the company's total share capital will change from 1,405,251,200 shares to 1,405,209,400 shares. The company stated that the repurchase and cancellation procedures are compliant, and the information is true and accurate

SANXING Medical will repurchase and cancel 41,800 restricted stocks

Ningbo Samsung Intelligent Electric Co., Ltd., a wholly-owned subsidiary of SANXING Medical, has signed a contract for the smart meter project in Egypt, amounting to USD 58.8 million (approximately RMB 419 million), accounting for 2.87% of the company's audited operating income for the fiscal year 2024. This contract will positively impact the company's operating performance and help the company expand its overseas market and enhance its competitive advantage

SANXING's subsidiary signs a 419 million yuan smart meter project in Egypt

300001

600885

002270

Guojin Securities released a research report indicating that the power equipment industry will continue to maintain stable operating performance in the first half of 2025, driven by global grid investment and emerging demand. It recommends focusing on AIDC, transformer exports, backbone network construction, and ultra-high voltage directions. In the first half of 2025, the power equipment sector is expected to achieve revenue of 170.1 billion yuan, a year-on-year increase of 13%, and a net profit attributable to the parent company of 14 billion yuan, a year-on-year increase of 14%. This is mainly attributed to the high profitability of leading companies' overseas businesses

TGOOD

Hongfa

HUAMING

Guotai Junan Securities: The operating performance of the power equipment sector is stable, focusing on emerging downstream and overseas markets

According to the Zhitong Finance APP, SANXING released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 7.972 billion yuan, a year-on-year increase of 13.93%. The net profit attributable to shareholders of the listed company was 1.23 billion yuan, a year-on-year increase of 6.93%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.136 billion yuan, a year-on-year increase of 5.34%. The basic earnings per share were 0.87 yuan

SANXING Medical released its performance for the first half of the year, with a net profit attributable to the parent company of 1.23 billion yuan, a year-on-year increase of 6.93%

SANXING(601567.SH)